Haemophilia : the official journal of the World Federation of Hemophilia · 2026
Plasma-Derived Factor VIIa/Factor X Improves Thrombin Generation Potential in a Plasma Model of Haemophilia A Supplemented With Direct Oral Anticoagulants.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Oh Shigeharu, Nakajima Yuto, Onishi Tomoko, Takami Eisuke, Nakano Hirotoshi, Nogami Keiji
Аннотация
BACKGROUND: Patients with haemophilia (PwH) complicated with atrial fibrillation require direct oral anticoagulants (DOACs) to prevent thrombosis, but still require haemostatic management to control bleeding. However, specific recommendations for managing bleeding in PwH with inhibitors (PwH-inh) receiving DOACs remain lacking. In Japan, plasma-derived (pd-) factor (F)VIIa/FX products are available for clinical management of PwH-inh, and may also be beneficial for haemostatic treatment in PwH-inh receiving DOACs.
AIM: To assess coagulation potential of pd-FVIIa/FX or other bypassing agents (BPAs) using an in vitro plasma model of PwHA-inh receiving DOACs.
METHODS: FVIII-deficient plasma was preincubated with anti-FVIII inhibitor (termed 'FVIII-depleted'). Pd-FVIIa/FX (1.5 µg/mL as FVIIa), recombinant (r)FVIIa (2.2 µg/mL), activated prothrombin complex concentrates (aPCC; 1.3 IU/mL), or FX preparation (520 nM) were added to FVIII-depleted plasmas supplemented with apixaban (100 ng/mL) or edoxaban (100 ng/mL). A similar model was prepared using plasma samples spiked with emicizumab (50 µg/mL). Coagulation potential was assessed utilizing thrombin generation assay (TGA).
RESULTS: The addition of pd-FVIIa/FX to FVIII-depleted plasmas supplemented with DOACs increased TG potential to near-normal range, irrespective of the presence of emicizumab. However, the addition of rFVIIa or FX alone to the FVIII-depleted plasma with DOACs exhibited coagulation potential below the normal range. The addition of aPCC and emicizumab to FVIII-depleted plasmas with DOACs enhanced TG potential above the normal range.
CONCLUSION: Pd-FVIIa/FX improved coagulation potential in the in vitro model plasma of PwHA-inh spiked with DOACs, irrespective of concomitant emicizumab. The clinical efficacy and safety of pd-FVIIa/FX require further evaluation.
AIM: To assess coagulation potential of pd-FVIIa/FX or other bypassing agents (BPAs) using an in vitro plasma model of PwHA-inh receiving DOACs.
METHODS: FVIII-deficient plasma was preincubated with anti-FVIII inhibitor (termed 'FVIII-depleted'). Pd-FVIIa/FX (1.5 µg/mL as FVIIa), recombinant (r)FVIIa (2.2 µg/mL), activated prothrombin complex concentrates (aPCC; 1.3 IU/mL), or FX preparation (520 nM) were added to FVIII-depleted plasmas supplemented with apixaban (100 ng/mL) or edoxaban (100 ng/mL). A similar model was prepared using plasma samples spiked with emicizumab (50 µg/mL). Coagulation potential was assessed utilizing thrombin generation assay (TGA).
RESULTS: The addition of pd-FVIIa/FX to FVIII-depleted plasmas supplemented with DOACs increased TG potential to near-normal range, irrespective of the presence of emicizumab. However, the addition of rFVIIa or FX alone to the FVIII-depleted plasma with DOACs exhibited coagulation potential below the normal range. The addition of aPCC and emicizumab to FVIII-depleted plasmas with DOACs enhanced TG potential above the normal range.
CONCLUSION: Pd-FVIIa/FX improved coagulation potential in the in vitro model plasma of PwHA-inh spiked with DOACs, irrespective of concomitant emicizumab. The clinical efficacy and safety of pd-FVIIa/FX require further evaluation.